Obefasimod (ABX464) in Ulcerative Colitis – What the Phase 3 Results Mean for U.S. Approval
Introduction – When Innovation Meets Momentum By Dr. Bruce E. Sands, MD, MS – Chief of Gastroenterology, Mount Sinai Hospital, New York If 2024 has shown us anything, it’s that the pace of medical innovation continues to far outstrip the speed of coverage reform. The ongoing CMS pause on broad coverage of GLP-1 anti-obesity drugs […]